Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

被引：0
|
作者：
Nadeem, Omar [1 ]
Redd, Robert [1 ]
Mo, Clifton [1 ]
Laubach, Jacob [1 ]
Richardson, Paul G. [1 ]
Prescott, Julia [1 ]
Marto, Marjorie [1 ]
Davie, Christine [1 ]
Ricciardi, Caroline [1 ]
Murphy, Elizabeth [1 ]
Bertoni, Meredith [1 ]
Choden, Dechen [1 ]
Magidson, Sophie [1 ]
Sheehan, Brian [1 ]
Shrestha, Hira [1 ]
Sperling, Adam S. [1 ]
O'Donnell, Elizabeth K. [2 ]
Ghobrial, Irene M. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-099
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 50 条
  • [21] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    Palumbo, Antonio
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria V.
    Mark, Tomer M.
    Qi, Ming
    Schecter, Jordan
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 754 - 766
  • [22] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [23] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [24] Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma
    Jakubowiak, A. J.
    Hofmeister, C.
    Campagnaro, E.
    Kendall, T.
    Zimmerman, T.
    Schlossman, R.
    Reece, D.
    Lonial, S.
    Hari, M.
    Hector-Word, Z.
    Griffith, K.
    Tendler, C.
    Esseltine, D. L.
    Bock, T.
    Kaminski, M.
    Dollard, A.
    Kelley, S.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S45 - S46
  • [25] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [26] Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma
    Kaiser, Martin F.
    Hall, Andrew
    Walker, Katrina
    Sherborne, Amy
    De Tute, Ruth M.
    Newnham, Nicola
    Roberts, Sadie
    Ingleson, Emma
    Bowles, Kristian
    Garg, Mamta
    Lokare, Anand
    Messiou, Christina
    Houlston, Richard S.
    Jackson, Graham
    Cook, Gordon
    Pratt, Guy
    Owen, Roger G.
    Drayson, Mark T.
    Brown, Sarah R.
    Jenner, Matthew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (23) : 3945 - +
  • [27] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    BLOOD, 2018, 132
  • [28] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
    Derman, Benjamin A.
    Cooperrider, Jennifer
    Rosenblatt, Jacalyn
    Avigan, David E.
    Rampurwala, Murtuza
    Barnidge, David
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Ramsland, Aubrianna
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [29] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    Nooka, A. K.
    Kaufman, J. L.
    Muppidi, S.
    Langston, A.
    Heffner, L. T.
    Gleason, C.
    Casbourne, D.
    Saxe, D.
    Boise, L. H.
    Lonial, S.
    LEUKEMIA, 2014, 28 (03) : 690 - 693
  • [30] Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
    A K Nooka
    J L Kaufman
    S Muppidi
    A Langston
    L T Heffner
    C Gleason
    D Casbourne
    D Saxe
    L H Boise
    S Lonial
    Leukemia, 2014, 28 : 690 - 693
12345